Updated:
Nexus NeuroTech
Nexus NeuroTech, launched in 2022 by Alex Tarrand and Sourav Sengupta, is a specialized investment firm focused on early-stage neurotechnology companies.
Nexus NeuroTech
NEXUS NEUROTECH, LLC is an SEC-registered investment adviser since 2023. It is registered with the SEC.
General information
Firm type
Asset Manager
Year founded
2022
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Alex Tarrand
Chief Executive Officer
Sourav Sengupta
Chief Investment Officer
Sector focus
Frequently asked questions
Which sectors does Nexus NeuroTech explicitly avoid?
Nexus NeuroTech does not invest in general digital health, traditional biopharma, medical devices outside neural interfaces, or pure software-as-a-service businesses. The firm's mandate excludes non-neurological therapeutic areas, wellness apps without regulatory clearance pathways, and hardware companies without brain-interface or neuromodulation core technology.
How does Nexus NeuroTech source its deals?
The firm sources primarily through academic neuroscience hubs, neural-engineering conferences, and relationships with university technology-transfer offices. Co-founders Tarrand and Sengupta have positioned the firm as a domain-specialist partner to neurotech founders, which generates proprietary flow distinct from auction processes run by generalist VCs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: